文献速递免疫规划

将RG1表位串联体整合入自佐剂鞭毛蛋白-L2疫苗可拓宽针对多种人乳头瘤病毒基因型皮肤攻击的持久保护

Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
PubMed 文献 · Vaccine · 2017-08-01

研究用细菌鞭毛蛋白(Fla)与L2保护表位融合,不加外源佐剂,经3次肌内注射免疫兔子,并在1、3、6或12个月后用含兔乳头瘤病毒基因组的HPV6/16/18/31/45/58假病毒攻击。Fla-HPV16 L2 11-200融合蛋白可诱导针对HPV16的持久保护,但交叉保护有限;加入HPV6/18/31/39/52的L2 17-38残基后,主动或被动免疫均拓宽保护谱,与含5或8种生殖道HPV型别11-88肽的铝佐剂L2多聚体疫苗相似。结论认为鞭毛蛋白融合L2多聚体无需外源佐剂即可提供持续超过1年的免疫,纳入17-38区可拓宽保护谱。

要点

  • Fla-HPV16 L2 11-200融合蛋白不加外源佐剂可诱导针对HPV16的持久保护,但交叉保护有限。
  • 加入HPV6/18/31/39/52的L2 17-38残基可拓宽保护谱,主动或被动免疫均可见。
  • 拓宽后的保护与含5或8种生殖道HPV型别11-88肽的铝佐剂L2多聚体疫苗相似。

核心结论

  • 鞭毛蛋白融合L2多聚体疫苗接种可提供持续超过1年的免疫,且无需外源佐剂。
  • 在此类多HPV型别融合物中纳入L2氨基酸17-38区可拓宽保护谱。

研究设计与样本

  • 研究在E. coli中生产Fla与L2保护表位(残基11-200、11-88和/或17-38,来自单一或多个人乳头瘤病毒型别)的融合蛋白,并评估其激活TLR5信号的能力。
  • 免疫原性评估:给予3次肌内注射Fla-L2多聚体(不加外源佐剂)后,于1、3、6或12个月后攻击,并与人用剂量L1 VLP疫苗(Gardasil和Cervarix)或铝佐剂配制的L2多聚体疫苗比较效力。
  • 血清抗体反应通过肽ELISA、体外中和试验和被动转移至 naïve 兔子评估,用完成主动免疫后1、3、6或12个月收集的混合免疫血清系列稀释测定终点保护滴度(EPPT)。
  • 效力通过在不同部位同时攻击含兔乳头瘤病毒(CRPV)基因组的HPV6/16/18/31/45/58「准病毒」后测定疣体积评估。

主要发现

  • 不加外源佐剂接种Fla-HPV16 L2 11-200融合蛋白可诱导针对HPV16的持久保护,但对其他HPV型别的交叉保护有限。
  • 肽映射数据提示17-38氨基酸区在赋予免疫中的重要性。
  • 将HPV6/18/31/39/52的L2残基17-38加入Fla-HPV16 L2 11-200或11-88可经由主动或被动免疫诱导更广泛的保护,与接种含5或8种生殖道HPV型别11-88肽的铝佐剂L2多聚体疫苗所见相似。

关键数值与推荐

  • Fla-HPV16 L2 11-200融合蛋白不加外源佐剂接种可诱导针对HPV16的持久保护,但交叉保护有限。
  • 加入HPV6/18/31/39/52的L2 17-38残基后,主动或被动免疫均拓宽保护谱,与含5或8种生殖道HPV型别11-88肽的铝佐剂L2多聚体疫苗相似。
  • 鞭毛蛋白融合L2多聚体疫苗接种提供持续超过1年的免疫,无需外源佐剂。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To achieve durable and broad protection against human papillomaviruses by vaccination with multimers of minor capsid antigen L2 using self-adjuvanting fusions with the toll-like receptor-5 (TLR5) ligand bacterial flagellin (Fla) instead of co-formulation with alum. METHODS: Fla fusions with L2 protective epitopes comprising residues 11-200, 11-88 and/or 17-38 of a single or multiple HPV types were produced in E. coli and their capacity to activate TLR5 signaling was assessed. Immunogenicity was evaluated serially following administration of 3 intramuscular doses of Fla-L2 multimer without exogenous adjuvant, followed by challenge 1, 3, 6 or 12months later, and efficacy compared to vaccination with human doses of L1 VLP vaccines (Gardasil and Cervarix) or L2 multimer formulated in alum. Serum antibody responses were assessed by peptide ELISA, in vitro neutralization assays and passive transfer to naïve rabbits in which End-Point Protection Titers (EPPT) were determined using serial dilutions of pooled immune sera collected 1, 3, 6 or 12months after completing active immunization. Efficacy was assessed by determining wart volume following concurrent challenge at different sites with HPV6/16/18/31/45/58 'quasivirions' containing cottontail rabbit papillomavirus (CRPV) genomes. RESULTS: Vaccination in the absence of exogenous adjuvant with Fla-HPV16 L2 11-200 fusion protein elicited durable protection against HPV16, but limited cross-protection against other HPV types. Peptide mapping data suggested the importance of the 17-38 aa region in conferring immunity. Indeed, addition of L2 residues 17-38 of HPV6/18/31/39/52 to a Fla-HPV16 L2 11-200 or 11-88 elicited broader protection via active or passive immunization, similar to that seen with vaccination with an alum-adjuvanted L2 multimer comprising the aa 11-88 peptides of five or eight genital HPV types. CONCLUSIONS: Vaccination with flagellin fused L2 multimers provided lasting (>1year) immunity without the need for an exogenous adjuvant. Inclusion of the L2 amino acid 17-38 region in such multi-HPV type fusions expanded the spectrum of protection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kalnin K, Chivukula S, Tibbitts T, et al. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes. Vaccine. 2017. PMID: 28778613. doi:10.1016/j.vaccine.2017.07.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。